Opening and closing the doors of the lockdown in Italy without forgetting lung cancer patients.


Journal

Interactive cardiovascular and thoracic surgery
ISSN: 1569-9285
Titre abrégé: Interact Cardiovasc Thorac Surg
Pays: England
ID NLM: 101158399

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 24 04 2020
revised: 12 05 2020
accepted: 18 05 2020
pubmed: 31 7 2020
medline: 8 9 2020
entrez: 31 7 2020
Statut: ppublish

Résumé

Coronavirus disease-19 (COVID-19) has rapidly spread to more than 200 countries all around the world, which are facing challenges in controlling its spread. The Italian Government initiated an unprecedented public health intervention to contain the epidemic by shutting down all people movements. Two weeks after the start of the lockdown period, the daily rate of patient admissions to hospitals significantly decreased. After 2 months, the quarantine progressively came to an end. A practical issue at this time is when and how the lockdown interventions should be relaxed since, without an effective vaccine, the general public still remains vulnerable. However, patient should not be placed at an increased risk of dying of lung cancer just to avoid COVID-19. Attention must be paid to all types of cancers and people should not hesitate to go to the hospital to be treated in time. All necessary actions should be taken by hospitals to minimize the risks of potential contagion, by designating differentiated routes and areas for patients potentially affected by COVID-19, while maintaining the highest standard of oncological care. If this 'cancer amnesia' situation persists, the mortality from lung neoplasms would far exceed that directly associated with the COVID-19 pandemic.

Identifiants

pubmed: 32728692
pii: 5878170
doi: 10.1093/icvts/ivaa106
pmc: PMC7454575
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

339-341

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Références

Ann Thorac Surg. 2015 Jun;99(6):1906-12; discussion 1913
pubmed: 25890663
Ann Thorac Surg. 2017 Apr;103(4):1070-1075
pubmed: 28110809
Interact Cardiovasc Thorac Surg. 2020 Jun 1;30(6):801-802
pubmed: 32271914
J Travel Med. 2020 May 18;27(3):
pubmed: 32181488
Clin Infect Dis. 2020 Apr 07;:
pubmed: 32255183

Auteurs

Luca Bertolaccini (L)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Lorenzo Spaggiari (L)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH